MUMBAI/DELHI : Reliance Industries Ltd (RIL) has sough the drug regulator’s permission to repurpose a generic drug used to treat tapeworm infestations for potential covid-19 treatment. “We are conducting the trial in moderate covid-19 patients who are at risk of moving to severe disease. Ltd to study the safety of the drug in covid-19 patients. However, the drug has not yet received authorization from the Indian regulator for the treatment of covid-19 patients. “I am not aware of any good study about Niclosamide in treatment of covid-19 that has been published in a journal.

Source: Mint June 03, 2021 19:07 UTC